Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction

Biomaterials

Volumn 45, Issue , 2015, Pages 56-63

  Sonnenberg, Sonya B ^a   Rane, Aboli A ^a   Liu, Cassie J ^b,c   Rao, Nikhil ^a   Agmon, Gillie ^a   Suarez, Sophia ^a   Wang, Raymond ^a   Munoz, Adam ^a   Bajaj, Vaibhav ^a   Zhang, Shirley ^a   Braden, Rebecca ^a   Schup Magoffin, Pamela J ^a   Kwan, Oi Ling ^d   DeMaria, Anthony N ^d   Cochran, Jennifer R ^b,c   Christman, Karen L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Stanford University   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Decellularization; Extracellular matrix; Growth factor; Hydrogel; Myocardial infarction

Indexed keywords

CARDIOLOGY; COLLAGEN;

CARDIOPROTECTIVE EFFECT; CLINICAL TRANSLATION; DECELLULARIZATION; EXTRACELLULAR MATRICES; GROWTH FACTOR; HEPATOCYTE GROWTH FACTOR; MYOCARDIAL INFARCTION; RECOMBINANT EXPRESSION;

HYDROGELS;

COLLAGEN GEL; RECOMBINANT SCATTER FACTOR; SCATTER FACTOR F; UNCLASSIFIED DRUG; HYDROGEL; PEPTIDE FRAGMENT; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; CONTROLLED STUDY; DENSITY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; EXTRACELLULAR MATRIX; FEMALE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HYDROGEL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; RAT; ANGIOGENESIS; ANIMAL; BLOOD VESSEL; CELL SIZE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; ECHOGRAPHY; FIBROSIS; HEART FUNCTION TEST; HUMAN; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; PIG; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; BLOOD VESSELS; CELL SIZE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX; FEMALE; FIBROSIS; HEART FUNCTION TESTS; HEPATOCYTE GROWTH FACTOR; HUMANS; HYDROGEL; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; PROTEIN ENGINEERING; PROTO-ONCOGENE PROTEINS C-MET; RATS, SPRAGUE-DAWLEY; SUS SCROFA; VENTRICULAR REMODELING;

EID: 84922022241     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.12.021     Document Type: Article

References (47)

1. Beohar N., Rapp J., Pandya S., Losordo D.W. Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. JAm Coll Cardiol 2010, 56:1287-1297.
2. Burchfield J.S., Dimmeler S. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenes Tissue Repair 2008, 1:4.
3. Liehn E.A., Postea O., Curaj A., Marx N. Repair after myocardial infarction, between fantasy and reality: the role of chemokines. JAm Coll Cardiol 2011, 58:2357-2362.
4. Mirotsou M., Jayawardena T.M., Schmeckpeper J., Gnecchi M., Dzau V.J. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. JMol Cell Cardiol 2011, 50:280-289.
5. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., Morello F., et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006, 20:661-669.
6. Nakamura T., Sakai K., Matsumoto K. Hepatocyte growth factor twenty years on: much more than a growth factor. JGastroenterol Hepatol 2011, 26(Suppl.1):188-202.
7. Ueda H., Nakamura T., Matsumoto K., Sawa Y., Matsuda H. Apotential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats. Cardiovasc Res 2001, 51:41-50.
8. Nakamura T., Mizuno S., Matsumoto K., Sawa Y., Matsuda H. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. JClin Invest 2000, 106:1511-1519.
9. Nakamura T., Matsumoto K., Mizuno S., Sawa Y., Matsuda H. Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am J Physiol Heart Circ Physiol 2005, 288:H2131-H2139.
10. Taniyama Y., Morishita R., Aoki M., Hiraoka K., Yamasaki K., Hashiya N., et al. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 2002, 40:47-53.
11. Li Y., Takemura G., Kosai K., Yuge K., Nagano S., Esaki M., et al. Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 2003, 107:2499-2506.
12. Jones D.S., Tsai P.C., Cochran J.R. Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists. Proc Natl Acad Sci U S A 2011, 13035-13040.
13. Liu C.J., Jones D.S., Tsai P.-C., Venkataramana A., Cochran J.R. An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist. FEBS Lett 2014, 588:4831-4837.
14. Zisch A.H., Lutolf M.P., Hubbell J.A. Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc Pathol 2003, 12:295-310.
15. Seif-Naraghi S.B., Horn D., Schup-Magoffin P.J., Christman K.L. Injectable extracellular matrix derived hydrogel provides a platform for enhanced retention and delivery of a heparin-binding growth factor. Acta Biomater 2012, 8:3695-3703.
16. Seif-Naraghi S.B., Salvatore M.A., Schup-Magoffin P.J., Hu D.P., Christman K.L. Design and characterization of an injectable pericardial matrix gel: a potentially autologous scaffold for cardiac tissue engineering. Tissue Eng Part A 2010, 16:2017-2027.
17. Singelyn J.M., Sundaramurthy P., Johnson T.D., Schup-Magoffin P.J., Hu D.P., Faulk D.M., et al. Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. JAm Coll Cardiol 2012, 59:751-763.
18. Christman K.L., Vardanian A.J., Fang Q., Sievers R.E., Fok H.H., Lee R.J. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. JAm Coll Cardiol 2004, 44:654-660.
19. Singelyn J.M., DeQuach J.A., Seif-Naraghi S.B., Littlefield R.B., Schup-Magoffin P.J., Christman K.L. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials 2009, 30:5409-5416.
20. Chen J.F., Murchison E.P., Tang R., Callis T.E., Tatsuguchi M., Deng Z., et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A 2008, 105:2111-2116.
21. Wang J., Song Y., Zhang Y., Xiao H., Sun Q., Hou N., et al. Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Res 2012, 22:516-527.
22. Davis G.E., Senger D.R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005, 97:1093-1107.
23. Haruyama T., Ajioka I., Akaike T., Watanabe Y. Regulation and significance of hepatocyte-derived matrix metalloproteinases in liver remodeling. Biochem Biophys Res Commun 2000, 272:681-686.
24. Esposito C., Parrilla B., De Mauri A., Cornacchia F., Fasoli G., Foschi A., et al. Hepatocyte growth factor (HGF) modulates matrix turnover in human glomeruli. Kidney Int 2005, 67:2143-2150.
25. Ruvinov E., Leor J., Cohen S. The effects of controlled HGF delivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. Biomaterials 2010, 31:4573-4582.
26. Cheng A.S., Yau T.M. Paracrine effects of cell transplantation: strategies to augment the efficacy of cell therapies. Semin Thorac Cardiovasc Surg 2008, 20:94-101.
27. Michalopoulos G.K. Liver regeneration: molecular mechanisms of growth control. FASEB J 1990, 4:176-187.
28. Nakamura T., Nishizawa T., Hagiya M., Seki T., Shimonishi M., Sugimura A., et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342:440-443.
29. Ruvinov E., Leor J., Cohen S. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials 2011, 32:565-578.
30. Jin H., Yang R., Li W., Ogasawara A.K., Schwall R., Eberhard D.A., et al. Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction. JPharmacol Exp Ther 2003, 304:654-660.
31. Ross J., Gherardi E., Mallorqui-Fernandez N., Bocci M., Sobkowicz A., Rees M., et al. Protein engineered variants of hepatocyte growth factor/scatter factor promote proliferation of primary human hepatocytes and in rodent liver. Gastroenterology 2012, 142:897-906.
32. Chirgadze D.Y., Hepple J.P., Zhou H., Byrd R.A., Blundell T.L., Gherardi E. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat Struct Biol 1999, 6:72-79.
33. Michieli P., Cavassa S., Basilico C., De Luca A., Mazzone M., Asti C., et al. An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. Nat Biotechnol 2002, 20:488-495.
34. Ono M., Sawa Y., Matsumoto K., Nakamura T., Kaneda Y., Matsuda H. Invivo gene transfection with hepatocyte growth factor via the pulmonary artery induces angiogenesis in the rat lung. Circulation 2002, 106:I264-I269.
35. Stewart N., Chade A.R. Renoprotective effects of hepatocyte growth factor in the stenotic kidney. Am J Physiol Ren Physiol 2013, 304:F625-F633.
36. Yang Z.J., Chen B., Sheng Z., Zhang D.G., Jia E.Z., Wang W., et al. Improvement of heart function in postinfarct heart failure swine models after hepatocyte growth factor gene transfer: comparison of low-, medium- and high-dose groups. Mol Biol Rep 2010, 37:2075-2081.
37. Messerli F.H. TIMPs, MMPs and cardiovascular disease. Eur Heart J 2004, 25:1475-1476.
38. Rajendran R., Rajeesh M.P., Shaikh S., Shanthi Pillai M.R. Expression of matrix metalloproteinases (MMP-1, MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in oral submucous fibrosis. Indian J Dent Res 2006, 17:161-166.
39. Han Y.P. Matrix metalloproteinases, the pros and cons, in liver fibrosis. JGastroenterol Hepatol 2006, 21(Suppl.3):S88-S91.
40. Li R.K., Li G., Mickle D.A., Weisel R.D., Merante F., Luss H., et al. Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 1997, 96:874-881.
41. Tomita H., Egashira K., Ohara Y., Takemoto M., Koyanagi M., Katoh M., et al. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998, 32:273-279.
42. Branton M.H., Kopp J.B. TGF-beta and fibrosis. Microbes Infect 1999, 1:1349-1365.
43. Lee A.A., Dillmann W.H., McCulloch A.D., Villarreal F.J. Angiotensin II stimulates the autocrine production of transforming growth factor-beta 1 in adult rat cardiac fibroblasts. JMol Cell Cardiol 1995, 27:2347-2357.
44. Takahashi N., Calderone A., Izzo N.J., Maki T.M., Marsh J.D., Colucci W.S. Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat ventricular myocytes. JClin Invest 1994, 94:1470-1476.
45. Jin H., Wyss J.M., Yang R., Schwall R. The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure. Curr Pharm Des 2004, 10:2525-2533.
46. Kubo H., Jaleel N., Kumarapeli A., Berretta R.M., Bratinov G., Shan X., et al. Increased cardiac myocyte progenitors in failing human hearts. Circulation 2008, 118:649-657.
47. Seif-Naraghi S.B., Singelyn J.M., Salvatore M.A., Osborn K.G., Wang J.J., Sampat U., et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med 2013, 5:173ra125.